MP Advisors is a Consultancy firm with an exclusive focus on Pharmaceuticals / Biotechnology sectors in the US, Europe, India, Japan and Russia. It was operating earlier as an international affiliate of Mehta Partners LLC since 1996. Today it has a highly motivated, qualified team of PhD's, MBA's and Pharmacist who apply their domain knowledge to develop proprietary data bases, understand dynamic regulatory laws across geographies, track and analyze latest trends in drug development, clinical trials and specific diseases. MP Advisors has insightful information on more than 200 pharma and Biotech companies around the globe as well as publishes reports on Key Opinion Leaders (Physician’s view) assessment, therapy class review of several classes (e.g. Oral anticoagulants, Hepatitis C, Obesity, Novel Drug Delivery systems, Biosimilars etc.), India and Japan generic opportunities and Paragraph IV Opportunities.

1. Completed Deals
MP Advisors
2013
www.mpadvisor.com
1

2. Range of Strategic Advisory Services Offered
Offered range of options to expand for a chemical conglomerate who had small pharma division
Offered Due Diligence services to a PE which considered investing in a formulation CRO
Offered retainer services to a CRAM company to keep its Ph I to patent expired API portfolio rich
Offered services to in-license patented products from biotech for home market ( a BRIC country)
Offered services to enter as frontline player into a regulated market for a client who had been
primarily a CMO in regulated market
Divested tail end brands of a MNC
Raised capital from a PE for Bio Similar CMO targeting regulated markets
Conceived Hybrid (Innovation and Generic) business model for die-hard innovator group and
made them appreciate rationale the new business model
Brought a Ph II company and large scale API producer together – a CRAM transaction for API co.
Advised a major MNC to withdraw from a take over transaction due to high risk of Para IV for
key product of company to be acquired
2

3. Range of Strategic Advisory Services Offered
Advised API company to re-prioritse its portfolio based on macro and therapeutic
competitive landscape
Advised a Global API company to not acquire a peptide API company
Strategic input to a US FDA approved Dermatology formulation company
Searched names of API where a leading NSAID API producer can leverage its
strength
Assisted a OTC company as sell side advisor
Assisted a co-Invested EU company divest its business in emerging market
Suggested expansion options to a Granules/Pallets producer
Identifying EU approved Sterile product manufacturer for a UK virtual company
SWOT analysis for a vaccine company aspiring to go in MAb Bio similar
3

4. Selected List of Deals by MP Advisors
2013 – Several Confidential Advisory projects within confidentiality period
2012 – Some Consultancy projects.
2011 – A couple of consultancy projects.
2010 – MP Advisors acted as sole advisor to Intas Biopharmaceuticals Pvt Ltd, to raise
private equity funding from TATA Capital
2009 – Sell side banker to Bangalore Genei, a Biologic company of Sanmar group, Merck
KgA acquired.
2009 – Parabolic Drugs Ltd shares to BTS Advisors/ Swiss Tech PE
2008 – MP conceptualized innovator-generic hybrid model and was strategic advisor
Daiichi-Sankyo on Ranbaxy’s acquisition.
2008 – Sold Tonira Pharma, only API company in India who earns half its revenue from
Japan, to IPCA.
4

5. Selected List of Deals by MP Advisors
2008 - Acquired an API company in Austria (Loba Chemie) for an Andhra Pradesh
based listed company (Shilpa Medicare)
2008 - Raised INR 200m for Marck Bioscience, a company specializing in Sterile
products from a PE
2007 – Drug Royalty - Assessed market potential of ~a dozen products up to 2015 on
behalf of an investor who looks at the royalty income stream
2006 – Conducted due-diligence on behalf of USV, an Indian company wanting to
acquire a Bio-Similar company in Ireland (Genmedix later acquired by Reliance Life
Sciences).
2006 - Advised an EU company BioMerieux in deciding the ranking of different
SBU’s of an Indian company, Shantha Biotech, it acquired
5

6. Selected List of Deals by MP Advisors
2006 - A US based NCE company (Cempra Pharmaceuticals) to source API for the
NCE from an Indian company (Alembic).
2005 - Advised an Indian conglomerate (Atul Ltd) to speed up its pharma division
growth.
2004 - Advised one of the top 10 MNC w r t global entry of Vaccine and Insulin
business.
2004 -Generated binding bid for an Indian OTC company (Paras Pharma) from an EU
company.
2004 - Divested brands of a leading EU company, Solvay in India as part of its global
strategy to Indoco Remedies (Karvol) and Alembic Pharmaceuticals (Yutopar).
2002 - Led first investment in a discovery based US biotech company, Onconova
(Philadelphia) by an Indian company Cadila.
6

7. Selected List of Deals by MP Advisors
2001 – Sold 35% stake in German Remedies Ltd. Held by four German companies i.e.
Asta Medica (Degussa Hull co), Boehringer Ingelheim, Schering AG & Dr. Falke.
Aggressive bidding was undertaken by Pharmacia, Bristol-Myers Squibb & Cadila.
2001 - Represented an EU company AstraZeneca to buy out its Indian partner, AstraIDL (A Hinduja Group Company).
2000- Established JV between a German (Altana) & an Indian company (Cadila) to
produce an “on patent” API (pantaprazole) for global need.
1996 - Licensed out the 1st Indian NCE (Glitazone PhI )from Dr. Reddy’s to an EU
company, Novo Nordisk.
1996 – Acquisition of a US NASDAQ listed Chapter-11 company, Caraco
Pharmaceuticals by an Indian company, Sun Pharmaceuticals (current value ~$250m).
7

8. MP Team – India
• Tarun Shah, MBA, is the founder of MP Advisors. He brings 22 years of global experience in
Corporate Finance and Investment Banking. He has significantly influenced the evolution of
cross border M&A activities in the pharmaceutical industry in recent years, having
conceptualized some of the important transactions as the major companies across the world
accelerate their efforts to create new business models in synchronization with the changing
times. Tarun has spotted novel investment (and divestment) ideas for Companies as well as
Fund Managers. 18 analysts working at MP Advisors provide active support to its overseas
clients.
• Devesh Singh, Pharmacist, MBA, brings over five years of consultancy and
industry experience since graduating with a degree in pharmacology from India. He
later earned a Masters in Business Administration from Stuttgart-IMT, Germany.
Prior to joining the MP Advisors team, Devesh worked with Alkem Labs, IMI
Consulting GmbH and Abbott GmbH & Co. At MP Advisors, his research focuses on
Japanese pharma companies.
8

9. MP Team – India
• Jagdish Gohil, Jagdish handles the Business Development portfolio of the company
and is responsible for identifying and researching new business opportunities for the
firm, whilst making improvements in the existing market and providing value oriented
service to existing clients. He is also responsible for IT Projects. Prior to joining MP
Advisors, he worked as a Systems Executive with one of the leading logistics
company of India.
• Mehul Mehta, A Microsoft Certified Networking Engineer, Mehul has more than 15
years experience of installation, designing, cable structuring and trouble-shooting.
Mehul also supports the administrative team at MP Advisors.
• Ripple Mehta, B. Pharmacy, MBA, brings solid academic back ground and three
years of industry experience. She started her career with Claris Life sciences in
international registration, and has worked with Dr. Reddy’s and Astra Zeneca in
Brand Management & Marketing.
9

10. MP Team – India
• Subita Srimal, Ph.D., founded a pharmaceutical company (now dormant) that manufactured a
diagnostic reagent, Carcinoscorpious amebocyte lysate (CAL) used for the detection of
pyrogens. CAL has been developed solely through her efforts. Subita is a member of MP’s
scientific think tank, and is responsible for providing scientific evaluation of the industry R&D
pipeline for our investment decisions. Subita received her postdoctoral training at Prof
Iwanaga’s lab in Kyushu University (Japan in 1984) and at Prof Carl Nathan’s lab, Cornell
University Medical College in New York (1987-1990). Previously, she worked at Tata Institute
of Fundamental Research, Mumbai and Indian Institute of Science, Bangalore as well as headed
her own lab at Institute of Microbial technology, Chandigarh. Subita has several publications
and patents to her credit.
• Sanjeev Mishra, B. Sc., MBA, works with the RS&MB team. Graduate of Chemistry and
earned an MBA in Investments from ICFAI Business School, Hyderabad. Prior to joining MP
Advisors team, he worked with Guggenheim-Transparent Value LLC, an asset management
company for three years.
• Khyati Thakrar, M.Sc. (Microbiology), holds a Master of Science from Sardar Patel Uni. She
has participated in a project at Bhabha Atomic Research Center, Mumbai, on Cloning &
Expression of mutant of uvrA gene (DC32) in Haemophillus influenza. Prior to joining MP, she
worked with Astral Pharmaceutical Industries in regulatory affairs and quality assurance
functions
10

11. MP Team – India
• Vijayakannan R., M.Pharm, PhD, MBA. His two years experience in formulation
development in the pharmaceutical industry and five years of University research has
familiarized him with all aspects of drug discovery, development and approval
processes. Prior to joining MP, he served as Deputy Manager, Scope eknowledge in
charge of managing a team of chemical, medical and life sciences professionals for
scientific database development. He holds an M.Pharm in Medicinal &
Pharmaceutical Chemistry from SGSITS, Indore (’05) and a PhD in Pharmacy from
Punjab University, Chandigarh (’07). He has several national and international
publications to his credit.
11

12. 12 3
Therapeutic Class Reports
Innovative Drug Delivery Systems: Novel Product and Formulation Technology
Licensing Opportunities
Risk – Reward of Developing a Herceptin Biosimilar – A Thorough Assessment
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors
Therapeutic Class Report Overview : Hepatitis C Virus Infection
Therapeutic Class Report Overview - Hemophilia
Therapeutic Class Report Overview - Rituxan Biosimilar
Therapeutic Class Report Overview - Japan Biosimilars
Cancer Vaccine: Hope or just Hype?
Hepatitis C Virus Infection: Protease Inhibitors Bring Change in the Treatment
Paradigm for Hepatitis
12

13. Therapeutic Class Reports
Metastatic Melanoma: Pipeline, Assessment and Market potential through 2017
Turn of The Decade: Novel GLP-1's To Emerge as the New Leader in Diabetes Class
Edoxaban - Potential Game changer in oral anticoagulant market
Psoriasis: Oral and Novel Biologics to Change Future Market Dynamic
Future of GPR Agonist
Positioning And Market Potential Of Cms-024 (Ysl, Tyroserleutide) In Hepatic Cancer In
China
Rheumatoid Arthritis: Battlefield At ACR '11 - Next Wave: Innovative Oral Drugs for RA
JAPAN DOMESTIC PHARMA - Competitive Landscape of Leading Therapy Classes UPDATE
13

14. Companies Tracked
INDIAN Generics
Aurobindo
Biocon Ltd
Cadila
Cipla
Dishman
Dr. Reddy's
Ipca
Lupin
Piramal Healthcare
Ranbaxy
Sun Pharma
Wockhardt
JAPAN Biotech/Biopharma
Astellas
Chugai
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Kyorin
Kyowa Hakko Kirin
Mitsubishi-Tanabe Pharma
Shionogi
Takeda
Torii Pharma
JAPAN Generics
Nippon Chem
Sawai
Towa
ARBP IN Equity
BIOS IN Equity
CDH IN Equity
CIPLA IN Equity
DISH IN Equity
DRRD IN Equity
IPCA IN Equity
LPC IN Equity
PIHC IN Equity
RBXY IN Equity
SUNP IN Equity
WPL IN Equity
4503 JP Equity
4519 JP Equity
4568 JP Equity
4506 JP Equity
4523 JP Equity
4569 JP Equity
4151 JP Equity
4508 JP Equity
4507 JP Equity
4502 JP Equity
4551 JP Equity
G BA - EU
LO L
AstraZeneca
GlaxoS ithkline
m
Novartis
NovoN
ordisk
Roche
Sanofi
G BA -U
LO L S
Bristol-M Squibb
yers
Eli Lilly
M
erck
Pfizer
A NU E
Z S quity
G L E
SK N quity
N SU E
V S quity
N VO DCEquity
O B
R GV Equity
O X
S FPEquity
AN
B YUSEquity
M
L U Equity
LY S
M USEquity
RK
P UE
FE S quity
4539 JP Equity
4555 JP Equity
4553 JP Equity
14

15. Companies Tracked
A ct iv e ly c o v e r ed R S c o m p a ni e s
A m a rin C o rp .
A m b it B io sc ie n c e
B a sile a P h a rm a
C e m p ra
C u ris
G al a p a go s
E n a nt a Ph a rm a
E n d oc y t e
H al o z y m e
Im m u no m e d i c s In c .
In c y te C o rp
In fi n ity P h a rm a
Isi s P ha r m a
M e d iv i r A B
M o rp h o sy s A G
O nc o n o v a T h e ra p e u ti c s
P h a rm a c y c lic s
S a re p ta T h er a p eu t ic s
S y m B i o Ph a rm a
T riu s T h e rp a e ut ic s
V iv u s
A ct iv e ly c o v e r ed M B c o m p a n ie s
A co r da T h e ra p e u tic s
A le x io n Ph a rm a ce u t ic a ls
A m g en In c
B io g e n I d ec
C e lg e n e
G ile a d
G rifo ls S A
R e ge n e ro n P h a rm a
O ny x
V er te x
T ic k e r N a m e
A M R N E q u it y
A M B I E q u ity
B S L N SW E q ui ty
C E M P E q u ity
C R I S E q u ity
G L P G B B E q u ity
E N T A E q u ity
E C Y T E q u it y
H A L O E q ui ty
IM M U E q u i ty
IN C Y E q u i ty
IN F I E qu i ty
ISI S E q u ity
M V IR B .S S E q u ity
M O R G R E qu i ty
O N T X E q ui ty
PC Y C E q u it y
SR PT E qu i ty
45 8 2 E qu i ty
A c q u ire d
V V U S E q u ity
A C O R E q ui ty
A L X N E q ui ty
A M G N E q u ity
B IIB E q u it y
C E L G E q u it y
G IL D E qu i ty
G R F E qu i ty
R E G N E q u ity
A c q u ire d
V R T X E q u ity
RS companies 'Monitored' - Not Actively Covered
Ablynx NV
ABLX BB Equity
Accentia Biopharma
ABPI Equity
Alnylam Pharma
ALNY Equity
Anthera Pharma
ANTH Equity
Elan
ELN Equity
Exelixis
EXEL Equity
GenMab
GEN.CO Equity
Immunogen, Inc
IMGN Equity
Intarcia Therapeutics
Pvt
Intercell AG
ICLL AV Equity
Intermune Inc
ITMN Equity
Omthera pharma
Pvt
Oncogenex Pharma
OGXI Equity
Oncothyreon
ONTY Equity
Optimer pharma
OPTR Equity
Protalix Therapeutics
PLX Equity
Seattle Genetics
SGEN Equity
Rigel Pharma
RIGL Equity
MB companies 'Monitored' - Not Actively Covered
Baxter pharma
BAX Equity
Cubist
CBST Equity
CSL
CSL Equity
Emergent Biosolutions
EBS Equity
Myriad Genetics
MYGN Equity
15

16. Address:
MP Advisors
B-203, Alkapuri Arcade,
R C Dutt Road,
Contact us:
Vadodara – 390007
(o) +91-265-2327096
+1.646.499.4569
(e) mp@mpadvisor.com
(w) www.mpadvisor.com
MP Advisors and/or its affiliates may hold a position in any security or financial instrument mentioned herein. The information contained in this
communication is solely intended for the addressee. Access by anyone other than the addressee is unauthorized. Disclosure, copying, and distribution of
this information are prohibited.
16